Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Luchetti, Andrea ^a,b   Walsh, Diana ^c   Rodger, Fay ^b   Clark, Graeme ^a   Martin, Tom ^d   Irving, Richard ^d   Sanna, Mario ^e,f   Yao, Masahiro ^g   Robledo, Mercedes ^h,i   Neumann, Hartmut P H ^j   Woodward, Emma R ^c,k   Latif, Farida ^c   Abbs, Stephen ^b   Martin, Howard ^b   Maher, Eamonn R ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e GRUPPO OTOLOGICO   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g YOKOHAMA CITY UNIVERSITY   (Japan)

^h Structural Biology and Biocomputing Programme   (Spain)

ⁱ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^j UNIVERSITY OF FREIBURG   (Germany)

^k BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FH GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; HIF2A GENE; HRAS GENE; MAX GENE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NF1 GENE; PARAGANGLIOMA; PCC GENE; PGL GENE; PHEOCHROMOCYTOMA; PIK3CA GENE; PRIORITY JOURNAL; PROTO ONCOGENE; RET GENE; SDHA GENE; SDHAF2 GENE; SDHB GENE; SDHD GENE; SEQUENCE ANALYSIS; SOMATIC MUTATION; TMEM127 GENE; TUMOR SUPPRESSOR GENE; VHL GENE;

EID: 84926609624     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/138573     Document Type: Article

References (57)

1. M. Jafri and E. R. Maher, "The genetics of phaeochromocytoma: using clinical features to guide genetic testing", European Journal of Endocrinology, vol. 166, no. 2, pp. 151-158, 2012.
2. A.-P. Gimenez-Roqueplo, P. L. Dahia, and M. Robledo, "An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes", Hormone and Metabolic Research, vol. 44, no. 5, pp. 328-333, 2012.
3. H. P. Neumann, B. Bausch, S. R. McWhinney et al., "Germlinemutations in nonsyndromic pheochromocytoma", The New England Journal of Medicine, vol. 346, no. 19, pp. 1459-1466, 2002.
4. N. Burnichon, L. Vescovo, L. Amar et al., "Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma", Human Molecular Genetics, vol. 20, no. 20, pp. 3974-3985, 2011.
5. N. Burnichon, A. Buffet, B. Parfait et al., "Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma", Human Molecular Genetics, vol. 21, no. 26, pp. 5397-5405, 2012.
6. Z. Zhuang, C. Yang, F. Lorenzo et al., "Somatic HIF2A gain-offunction mutations in paraganglioma with polycythemia", The New England Journal of Medicine, vol. 367, no. 10, pp. 922-930, 2012.
7. I. Comino-Méndez, A. A. De Cubas, C. Bernal et al., "Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis", Human Molecular Genetics, vol. 22, no. 11, pp. 2169-2176, 2013.
8. E. Rattenberry, L. Vialard, A. Yeung et al., "A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma", Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 7, pp. E1248-E1256, 2013.
9. B. E. Baysal, R. E. Ferrell, J. E. Willett-Brozick et al., "Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma", Science, vol. 287, no. 5454, pp. 848-851, 2000.
10. S. Niemann and U. Müller, "Mutations in SDHC cause autosomal dominant paraganglioma, type 3", Nature Genetics, vol. 26, no. 3, pp. 268-270, 2000.
11. D. Astuti, F. Latif, A. Dallol et al., "Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma", The American Journal of Human Genetics, vol. 69, no. 1, pp. 49-54, 2001.
12. N. Burnichon, J.-J. Brière, R. Libé et al., "SDHA is a tumor suppressor gene causing paraganglioma", Human Molecular Genetics, vol. 19, no. 15, pp. 3011-3020, 2010.
13. G. Eisenhofer, T.-T. Huynh, K. Pacak et al., "Distinct gene expression profiles in norepinephrine- and epinephrineproducing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome", Endocrine-Related Cancer, vol. 11, no. 4, pp. 897-911, 2004.
14. E. López-Jiménez, G. Gómez-López, L. J. Leandro-Garcí et al., "Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas", Molecular Endocrinology, vol. 24, no. 12, pp. 2382-2391, 2010.
15. P. L. Dahia, K. N. Ross, M. E. Wright et al., "AHIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas", PLoS Genetics, vol. 1, pp. 172-180, 2005.
16. A. Vicha, Z. Musil, and K. Pacak, "Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options", Current Opinion in Endocrinology, Diabetes and Obesity, vol. 20, no. 3, pp. 186-191, 2013.
17. P. L. M. Dahia, K. Hao, J. Rogus et al., "Novel pheochromocytoma susceptibility loci identified by integrative genomics", Cancer Research, vol. 65, no. 21, pp. 9651-9658, 2005.
18. J. Favier and A.-P. Gimenez-Roqueplo, "Pheochromocytomas: the (pseudo)-hypoxia hypothesis", Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 24, no. 6, pp. 957-968, 2010.
19. J. Crona, A. Delgado Verdugo, R. Maharjan et al., "Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing", Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 7, pp. E1266-E1271, 2013.
20. L. Oudijk, R. Ronald, R. R. De Krijger et al., "H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series", The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, pp. E1376-E1380, 2014.
21. J. S. Ross and M. Cronin, "Whole cancer genome sequencing by next-generation methods", American Journal of Clinical Pathology, vol. 136, no. 4, pp. 527-539, 2011.
22. A. Blanes, J. J. Sanchez-Carrillo, and S. J. Diaz-Cano, "Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, 2006.
23. A. Cascon, S. Ruiz-Llorente, M. F. Fraga et al., "Genetic and epigenetic profile of sporadic pheochromocytomas", Journal of Medical Genetics, vol. 41, no. 3, article e30, 2004.
24. J. Sandgren, R. Andersson, A. Rada-Iglesias et al., "Integrative epigenomic and genomic analysis of malignant pheochromocytoma", Experimental and Molecular Medicine, vol. 42, no. 7, pp. 484-502, 2010.
25. A. Hering, M. Guratowska, P. Bucsky et al., "Characteristic genomic imbalances in pediatric pheochromocytoma", Genes, Chromosomes and Cancer, vol. 45, no. 6, pp. 602-607, 2006.
26. H. Dannenberg, E. J. M. Speel, J. Zhao et al., "Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas", American Journal of Pathology, vol. 157, no. 2, pp. 353-359, 2000.
27. E. Edstrom, E. Mahlamaki, B. Nord et al., "Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology", The American Journal of Pathology, vol. 156, no. 2, pp. 651-659, 2000.
28. F. H. Van Naderveen, E. Korpershoek, R. J. De Leeuw et al., "Array-comparative genomic hybridization in sporadic benign pheochromocytomas", Endocrine-Related Cancer, vol. 16, no. 2, pp. 505-513, 2009.
29. J. Sandgren, T. Diaz De Stahl, R. Andersson et al., "Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis", Endocrine-Related Cancer, vol. 17, no. 3, pp. 561-579, 2010.
30. D. Astuti, F. Douglas, T. W. J. Lennard et al., "Germline SDHD mutation in familial phaeochromocytoma", The Lancet, vol. 357, no. 9263, pp. 1181-1182, 2001.
31. C. D. E. Margetts, D. Astuti, D. C. Gentle et al., "Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, Kv DMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas", Endocrine-Related Cancer, vol. 12, no. 1, pp. 161-172, 2005.
32. J. Geli, N. Kiss, M. Karimi et al., "Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior", Clinical Cancer Research, vol. 14, no. 9, pp. 2551-2559, 2008.
33. P. L. M. Dahia, "Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity", Nature Reviews Cancer, vol. 14, no. 2, pp. 108-119, 2014.
34. Y. Aoki, T. Niihori, H. Kawame et al., "Germline mutations in HRAS proto-oncogene cause Costello syndrome", Nature Genetics, vol. 37, no. 10, pp. 1038-1040, 2005.
35. S. M. Kumar, J. Dai, S. Li et al., "Human skin neural crest progenitor cells are susceptible to BRAF V600E-induced transformation", Oncogene, vol. 33, no. 7, pp. 832-841, 2014.
36. K. T. Flaherty, I. Puzanov, K. B. Kim et al., "Inhibition of mutated, activated BRAF in metastatic melanoma", The New England Journal of Medicine, vol. 363, no. 9, pp. 809-819, 2010.
37. D. N. Hayes, A. S. Lucas, T. Tanvetyanon et al., "Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements", Clinical Cancer Research, vol. 18, no. 7, pp. 2056-2065, 2012.
38. D. A. Liebner and M. H. Shah, "Thyroid cancer: pathogenesis and targeted therapy", Therapeutic Advances in Endocrinology and Metabolism, vol. 2, no. 5, pp. 173-195, 2011.
39. M. Xing, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocrine Reviews, vol. 28, no. 7, pp. 742-762, 2007.
40. S. Seitz, K. Poppe, J. Fischer et al., "Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: associationwith clinicopathological parameters", The Journal of Pathology, vol. 194, pp. 318-326, 2001.
41. M. Risio, L. Casorzo, L. Chiecchio, G. De Rosa, and F. P. Rossini, "Deletions of 17p are associated with transition from early to advanced colorectal cancer", Cancer Genetics and Cytogenetics, vol. 147, no. 1, pp. 44-49, 2003.
42. X. Y. Guan, J. S. Sham, L. S. Tai, Y. Fang, H. Li, and Q. Liang, "Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma", Cancer Genetics and Cytogenetics, vol. 140, no. 1, pp. 45-48, 2003.
43. B.-J. Petri, E.-J. M. Speel, E. Korpershoek et al., "Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas", Modern Pathology, vol. 21, no. 4, pp. 407-413, 2008.
44. T. Yoshimoto, M. Naruse, Z. Zeng et al., "The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas", Journal of Endocrinology, vol. 159, no. 2, pp. 247-255, 1998.
45. K. K. Herfarth, M. R. Wick, H. N. Marshall, E. Gartner, S. Lum, and J. F. Moley, "Absence of TP53 alterations in pheochromocytomas andmedullary thyroid carcinomas", Genes, Chromosomes and Cancer, vol. 20, no. 1, pp. 24-29, 1997.
46. B. C. Figueiredo, R. Sandrini, G. P. Zambetti et al., "Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation", Journal of Medical Genetics, vol. 43, no. 1, pp. 91-96, 2006.
47. E. Michalkiewicz, R. Sandrini, B. Figueiredo et al., "Clinical and outcome characteristics of children with adrenocortical tumors: a report from the international pediatric adrenocortical tumor registry", Journal of Clinical Oncology, vol. 22, no. 5, pp. 838-845, 2004.
48. M. I. W. Achatz, M. Olivier, F. L. Calvez et al., "The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families", Cancer Letters, vol. 245, no. 1-2, pp. 96-102, 2007.
49. J. G. Assumpção, A. L. Seidinger, M. J. Mastellaro et al., "Association of the germline TP53 R337H mutation with breast cancer in Southern Brazil", BMC Cancer, vol. 8, article 357, 2008.
50. E. I. Palmero, L. Schuler-Faccini, M. Caleffi et al., "Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil", Cancer Letters, vol. 261, no. 1, pp. 21-25, 2008.
51. G. Custodio, G. R. Taques, B. C. Figueiredo et al., "Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil", PLoS ONE, vol. 6, no. 3, Article ID e18015, 2011.
52. A. L. Seidinger, M. J. Mastellaro, F. Paschoal Fortes et al., "Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil", Cancer, vol. 117, no. 10, pp. 2228-2235, 2011.
53. H. Yang, D. Ye, K.-L. Guan, and Y. Xiong, "IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives", Clinical Cancer Research, vol. 18, no. 20, pp. 5562-5571, 2012.
54. J. Gaal, N. Burnichon, E. Korpershoek et al., "Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas", The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 3, pp. 1274-1278, 2010.
55. A.-P. Gimenez-Roqueplo, J. Favier, P. Rustin et al., "Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas", Cancer Research, vol. 63, no. 17, pp. 5615-5621, 2003.
56. F. M. Brouwers, G. Eisenhofer, J. J. Tao et al., "High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4505-4509, 2006.
57. C. J. Ricketts, J. R. Forman, E. Rattenberry et al., "Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD", Human Mutation, vol. 31, no. 1, pp. 41-51, 2010.